alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit 35.1

Servicer Compliance Statement of AmeriCredit Financial Services, Inc.

This Annual Statement as to Compliance is delivered to you pursuant to Section 4.10 (a) of the Sale and Servicing Agreement dated as of
April 12, 2012 (the Agreement) and Item 1123 of Regulation AB, executed in connection with the formation of AmeriCredit Automobile Receivables Trust 2012-2 (the Trust), the issuance of the Notes by the Trust and the
closing of the transactions and the execution and delivery of the various documents by AmeriCredit Financial Services, Inc. (the Servicer) and AFS SenSub Corp. in connection therewith. The capitalized terms used herein shall have the
same meanings as in the Agreement.

The undersigned certifies that I am the Executive Vice President, Corporate Controller and Chief
Accounting Officer of the Servicer. I further certify as follows:



| | 1. | I have conducted, or caused to be conducted under my supervision, a review of the Servicer during the preceding period from January 1, 2015 through December 31, 2015, and its performance under the Agreement.
| | -- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



| | 2. | To the best of my knowledge, following such review, the Servicer has fulfilled all its obligations under the Agreement throughout such period, and, to the best of my knowledge, there has been no default in the
fulfillment of any such obligation.
| | -- | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AmeriCredit Financial Services, Inc.



|    |  |                                         |  |  |  |  |  |                      
|--- |  | --------------------------------------- |  |  |  |  |  | ---------------------
|By: |  | /s/ Connie Coffey                       |  |  |  |  |  | Dated: March 25, 2016
|    |  | Connie Coffey                           |  |  |  |  |  |                      
|    |  | Executive Vice President, Corporate     |  |  |  |  |  |                      
|    |  | Controller and Chief Accounting Officer |  |  |  |  |  |
#### Hazel TONEY, Jr., Administrator of the Estate of Keysha Lashawn Toney (deceased), Respondent, v. SOUTH CAROLINA DEPARTMENT OF EDUCATION, Appellant-Petitioner.

(327 S. E. (2d) 326)

Supreme Court

May 24, 1984.

ORDER

Appellant-Petitioner requests the Court to issue a writ of *certiorari*to review the decision of the Court of Appeals in *Toney v. South Carolina Department of Education,*279 S. C. 484, 309 S. E. (2d) 773 (Ct. App. 1983).

We deny the writ as to Question 1 and grant the writ as to Question 2.

The Appendix shall be docketed as the Transcript of Record as of the date of this order. Appellant-Petitioner shall file eight additional copies of the Appendix by the deadline for filing the petitioner’s brief. The materials in the Appendix are not required to be certified copies. The parties are directed to file briefs in accordance with Rule 8 of the Rules of Practice of the Supreme Court, except only one original brief and nine copies shall be required. This matter shall proceed in conformity with the Court’s rules.
DENY and Opinion Filed January 25, 2022 

S 

In The 

Court of Appeals 

Fifth District of Texas at Dallas 

No. 05-22-00041-CV 

IN RE DAVID S. GRANTHAM, Relator 

Original Proceeding from the 469th Judicial District Court 

Collin County, Texas 

Trial Court Cause No. 469-52594-2016 

MEMORANDUM OPINION 

Before Justices Schenck, Reichek, and Carlyle 

Opinion by Justice Reichek 

In this original proceeding, relator challenges the trial court’s December 2, 

2021 order denying relator’s special appearance plea to the jurisdiction and second 

amended motion to transfer venue in the underlying proceedings. 

Entitlement to mandamus relief requires relator to show that the trial court 

clearly abused its discretion and that he lacks an adequate appellate remedy. In re 

Prudential Ins. Co., 148 S.W.3d 124, 135–36 (Tex. 2004) (orig. proceeding). As the 

party seeking relief, relator has the burden of providing the Court with a certified or 

sworn copy of the challenged order and every document that is material to 

establishing relator’s right to mandamus relief. See TEX. R. APP. P. 52.3(k), 52.7(a); 
 –2– 

In re Butler, 270 S.W.3d 757, 759 (Tex. App.—Dallas 2008, orig. proceeding) 

(requiring relator to submit a record containing certified or sworn copies). 

Relator has failed to provide the Court with a copy of the challenged order or 

any other document material to establishing a right to mandamus relief. We 

conclude relator has not met his burden to prove an entitlement to the relief 

requested. Accordingly, we deny the petition for writ of mandamus without 

prejudice to refiling a petition with a record that complies with Texas Rule of 

Appellate Procedure 52. See TEX. R. APP. P. 52.3(k), 52.7(a). 

220041F.P05 

/Amanda L. Reichek/

AMANDA L. REICHEK 

JUSTICE
Exhibit 31.1



CERTIFICATIONS UNDER SECTION 302



I, Paul J. Kelly, certify that:



1. I have reviewed this quarterly report of Orchid BioSciences, Inc.;



2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material
fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;



3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present
in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;



4. The registrants other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as
defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:



a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;



b) evaluated the effectiveness of the
registrants disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and



c) disclosed in this report any change in the
registrants internal control over financial reporting that occurred during the registrants most recent fiscal quarter (the registrants fourth fiscal quarter in the case of an annual report) that has materially affected, or is
reasonably likely to materially affect, the registrants internal control over financial reporting; and



5. The registrants other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrants auditors and the audit committee of the registrants board of directors (or persons performing the equivalent functions):



a) all significant deficiencies and material weaknesses in the design or operation of internal control over
financial reporting which are reasonably likely to adversely affect the registrants ability to record, process, summarize and report financial information; and



b) any fraud, whether or not material, that involves management or other employees who have a significant
role in the registrants internal control over financial reporting.



Date: November 12, 2004



|                             
|-----------------------------
|/S/ PAUL J. KELLY, MD        
|Paul J. Kelly, MD            
|Chief Executive Officer      
|(Principal Executive Officer)
UNPUBLISHED

UNITED STATES COURT OF APPEALS

FOR THE FOURTH CIRCUIT

No. 00-1677

JAMES E. BEASLEY,

Plaintiff - Appellant,

versus

KENNETH S. APFEL, COMMISSIONER OF SOCIAL SECURITY,

Defendant - Appellee.

Appeal from the United States District Court for the District of

South Carolina, at Charleston. G. Ross Anderson, Jr., District

Judge. (CA-99-1568-2-13AJ)

Submitted: October 17, 2000 Decided: November 1, 2000

Before LUTTIG, MICHAEL, and TRAXLER, Circuit Judges.

Affirmed by unpublished per curiam opinion.

James Beasley, Appellant Pro Se. Michele M. Kelley, SOCIAL SECURITY ADMINISTRATION, Denver, Colorado, for Appellee.

Unpublished opinions are not binding precedent in this circuit.

See Local Rule 36(c).
1 We note that the complaint in this action was docketed in

the district court on May 18, 1999, rather than on May 26.

2 Although the district court’s judgment is marked as “filed”

on March 24, 2000, the district court’s record shows that it was

entered on the docket sheet on March 27. Pursuant to Rules 58 and

79(a) of the Federal Rules of Civil Procedure, it is the date that

the judgment or order was entered on the docket sheet that we take

as the effective date of the district court’s decision. See Wilson

v. Murray, 806 F.2d 1232, 1234-35 (4th Cir. 1986).

2

PER CURIAM:

James Beasley appeals the district court’s order dismissing

his complaint as untimely filed. We have reviewed the record and

the district court’s order adopting the recommendation of the magistrate judge and find no reversible error.1 We therefore affirm

on the reasoning of the district court. See Beasley v. Apfel, No.

CA-99-1568-2-13AJ (D.S.C. Mar. 27, 2000).2 We dispense with oral

argument because the facts and legal contentions are adequately

presented in the materials before the court and argument would not

aid the decisional process.

AFFIRMED
First Amendment, dated June 3, 2010.



 Exhibit 10.1 

FIRST AMENDMENT TO 

MYRIAD PHARMACEUTICALS, INC. 

Executive Severance and Change in Control Agreement 

This First Amendment to Myriad Pharmaceuticals, Inc. Executive Severance and Change in Control Agreement (this “Amendment”) is
made and entered into this 3rd day of June, 2010, by and between Barbara Berry (the “Executive”) and Myriad Pharmaceuticals, Inc. (the “Company”). 

W I T N E S S E T H 

WHEREAS, the Executive and the Company entered into an Executive Severance and Change in Control Agreement dated February 1,
2010 (the “Agreement”); and 
 WHEREAS, the Executive and the Company desire to amend the Agreement to change
the severance benefits Executive will receive upon termination of Executive’s employment from the Company under certain circumstances. 

NOW, THEREFORE, in consideration of the promises and mutual covenants and agreements contained herein and other good and valuable
consideration, the receipt of which is hereby acknowledged, the parties hereto agree as follows: 
 1. Section 4.2(a) of
the Agreement is amended in its entirety to read as follows: 
 (a) Termination Without Cause or for Good
Reason. If the Executive’s employment with the Company is terminated by the Company (other than for Cause, Disability or death) or by the Executive for Good Reason, then the Executive shall be entitled to the following benefits: 

(i) the Company shall pay to the Executive the following amounts: 

(1) the Executive’s base salary through the Date of Termination; 

(2) any accrued vacation pay to the extent not previously paid; 

(3) $204,883, in a lump sum, in cash, within 30 days after the Date of Termination; 

(ii) if the Executive is covered under the Company’s group health plan immediately prior to the Date of Termination,
then if the Executive timely elects to continue such coverage under COBRA, the Company will pay the premium for the Executive’s COBRA coverage until the earlier of (A) six months from the Date of Termination and (B) the date the
Executive becomes covered under another group health plan; and 







 (iii) any equity award(s) issued to the Executive shall be governed by and
subject to the terms and conditions of the applicable award agreement. 
 2. The parties hereby agree that the Agreement will
continue to be in full force and effect as modified by the terms of this Amendment. 
 IN WITNESS WHEREOF, the
parties have executed this Amendment as of the day and year first written above. 
  

					
	MYRIAD PHARMACEUTICALS, INC.
		
	By:	 	 /s/ Adrian N. Hobden

		 	Name:	 	Adrian N. Hobden, Ph.D.
		 	Title:	 	President and CEO
	
	 /s/ Barbara Berry

	Barbara Berry


  

 2
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Farm Credit Administration

# TIME AND DATE: 

9:00 a.m., Thursday, January 13, 2022.

# PLACE: 

                        Because of the COVID-19 pandemic, the public may only virtually attend the open portions of this meeting. If you would like to virtually attend, at least 24 hours in advance, visit                         *FCA.gov,*                         select “Newsroom,” and then select “Events.” From there, access the linked “Instructions for board meeting visitors.”                    

# STATUS: 

Parts of this meeting will be open to the public. The rest of the meeting will be closed to the public.

# MATTERS TO BE CONSIDERED:

## Portions Open to the Public

    - Approval of December 9, 2021 minutes
    - Small Association Workgroup
    - Bookletter-068 Tier 1/Tier 2 Capital Framework Guidance (Revised)
    - OIG Year in Review and Report on FY 2021 Financial Statement Audit

## Portions Closed to the Public

Executive Session with Financial Statement Auditors [1] 

Report on FY 2021 FISMA Audit [2] 

# CONTACT PERSON FOR MORE INFORMATION: 

If you need more information, need assistance for accessibility reasons, or have questions, contact Ashley Waldron, Secretary to the Board. Telephone: 703-883-4009. TTY: 703-883-4056.

Ashley Waldron,

Secretary to the Board.

# Footnotes

1.                             Session Closed-Exempt pursuant to 5 U.S.C. Section 552b(c)(2).                    
        Back to Citation      

2.                             Session Closed-Exempt pursuant to 5 U.S.C. Section 552b(c)(2).                    
        Back to Citation      

[FR Doc. 2022-00003 Filed 1-3-22; 4:15 pm]

BILLING CODE 6705-01-P
[Federal Register Volume 80, Number 77 (Wednesday, April 22, 2015)]
[Notices]
[Page 22524]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-09340]


-----------------------------------------------------------------------

FEDERAL RESERVE SYSTEM


Change in Bank Control Notices; Acquisitions of Shares of a Bank 
or Bank Holding Company

    The notificants listed below have applied under the Change in Bank 
Control Act (12 U.S.C. 1817(j)) and Sec.  225.41 of the Board's 
Regulation Y (12 CFR 225.41) to acquire shares of a bank or bank 
holding company. The factors that are considered in acting on the 
notices are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)).
    The notices are available for immediate inspection at the Federal 
Reserve Bank indicated. The notices also will be available for 
inspection at the offices of the Board of Governors. Interested persons 
may express their views in writing to the Reserve Bank indicated for 
that notice or to the offices of the Board of Governors. Comments must 
be received not later than May 7, 2015.
    A. Federal Reserve Bank of New York (Ivan Hurwitz, Vice President) 
33 Liberty Street, New York, New York 10045-0001:
    1. Basswood Capital Management, LLC, New York, New York; funds for 
which Basswood Partners, LLC serves as General Partner and for which 
Basswood Capital Management, LLC serves as Investment Manager (Basswood 
Opportunity Partners, LP; Basswood Financial Fund, LP; Basswood 
Financial Long Only Fund, LP); a fund for which Basswood Enhanced Long 
Short GP, LLC serves as General Partner and for which Basswood Capital 
Management, LLC serves as Investment Manager (Basswood Enhanced Long 
Short Fund, LP); funds for which Basswood Capital Management, LLC 
serves as Investment Manager (Basswood Opportunity Fund, Inc.; Basswood 
Financial Fund, Inc.; BCM Select Equity I Master, Ltd.); Basswood 
Capital Management, LLC, as investment adviser to a managed account; 
Matthew Lindenbaum; Bennett Lindenbaum; Nathan Lindenbaum and Shai 
Tambor as Trustees for Abigail Tambor 2012 Children's Trust; Nathan 
Lindenbaum; Yitzchak Jacobwitz, I. Marc Guttmann and David J. Katz as 
Trustees for Nathan J Lindenbaum 1995 Children Trust; Nathan Lindenbaum 
and Shari Lindenbaum as Members of Naftali Asher Investments LLC; 
Nathan Lindenbaum and Shai Tambor as Trustees for Victoria Feder & 
Benjamin Feder 2012 Children's Trust; Ray Lindenbaum as Trustee for 
Victoria & Ben Feder's 1996 Children's Trust; Marcel Lindenbaum; and 
Nathan Lindenbaum as Trustee for Shari A. Lindenbaum 1994 Children's 
Trust, all of New York, New York; to collectively acquire voting shares 
of Bridge Bancorp, Inc., and thereby indirectly acquire voting shares 
of The Bridgehampton National Bank, both in Bridgehampton, New York.

    Board of Governors of the Federal Reserve System, April 17, 
2015.
Margaret McCloskey Shanks,
Deputy Secretary of the Board.
[FR Doc. 2015-09340 Filed 4-21-15; 8:45 am]
 BILLING CODE 6210-01-P
[Federal Register Volume 80, Number 77 (Wednesday, April 22, 2015)]
[Notices]
[Page 22553]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-09332]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-392]


Importer of Controlled Substances Application: PHARMACORE

ACTION: Notice of application.

-----------------------------------------------------------------------

DATES: Registered bulk manufacturers of the affected basic class, and 
applicants therefore, may file written comments on or objections to the 
issuance of the proposed registration in accordance with 21 CFR 
1301.34(a) on or before May 22, 2015. Such persons may also file a 
written request for a hearing on the application pursuant to 21 CFR 
1301.43 on or before May 22, 2015.

ADDRESSES: Written comments should be sent to: Drug Enforcement 
Administration, Attention: DEA Federal Register Representative/ODXL, 
8701 Morrissette Drive, Springfield, Virginia 22152. Request for 
hearings should be sent to: Drug Enforcement Administration, Attention: 
Hearing Clerk/LJ, 8701 Morrissette Drive, Springfield, Virginia 22152. 
Comments and requests for any hearings on applications to import 
narcotic raw material are not appropriate. 72 FR 3417 (January 25, 
2007).

SUPPLEMENTARY INFORMATION: The Attorney General has delegated his 
authority under the Controlled Substances Act to the Administrator of 
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority 
to exercise all necessary functions with respect to the promulgation 
and implementation of 21 CFR part 1301, incident to the registration of 
manufacturers, distributors, dispenser, importers, and exporters of 
controlled substances (other than final orders in connection with 
suspension, denial, or revocation of registration) has been redelegated 
to the Deputy Assistant Administrator of the DEA Office of Diversion 
Control (``Deputy Assistant Administrator'') pursuant to section 7 of 
28 CFR part 0, appendix of subpart R.
    In accordance with 21 CFR 1301.34(a), this is notice that on August 
29, 2014, Pharmacore, 4180 Mendenhall Oaks Parkway, High Point, North 
Carolina 27265 applied to be registered as an importer of poppy straw 
concentrate (9670), a basic class of controlled substance listed in 
schedule II.
    The company plans to import the listed controlled substance to 
manufacture bulk controlled substance intermediates for sale to its 
customers.

    Dated: April 14, 2015.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[FR Doc. 2015-09332 Filed 4-21-15; 8:45 am]
 BILLING CODE 4410-09-P
Exhibit 31.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO
RULE 13a-14 OF THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302
OF THE SARBANES-OXLEY ACT OF 2002 I, Shant S.
Hovnanian, certify that: 1. I have
reviewed this annual report on Form 10-K of Speedus Corp.; 2. Based on my
knowledge, this report does not contain any untrue statement of a material fact
or omit to state a material fact necessary to make the statements made, in
light of the circumstances under which such statements were made, not
misleading with respect to the period covered by this report; 3. Based on my
knowledge, the financial statements, and other financial information included
in this report, fairly present in all material respects the financial condition,
results of operations and cash flows of the registrant as of, and for, the
periods presented in this report; 4. The
registrants other certifying officer and I are responsible for establishing
and maintaining disclosure controls and procedures (as defined in Exchange Act
Rules 13a-15(e) and 15d-15(e)) for the registrant and have: (a)
Designed such disclosure controls and procedures, or caused such disclosure
controls and procedures to be designed under our supervision, to ensure that
material information relating to the registrant, including its consolidated
subsidiaries, is made known to us by others within those entities, particularly
during the period in which this report is being prepared; (b)
Evaluated the effectiveness of the registrants disclosure controls and
procedures and presented in this report our conclusions about the effectiveness
of the disclosure controls and procedures, as of the end of the period covered
by this report based on such evaluation; and (c)
Disclosed in this report any change in the registrants internal control over
financial reporting that occurred during the registrants most recent fiscal
quarter (the registrants fourth fiscal quarter in the case of an annual
report) that has materially affected, or is reasonably likely to materially
affect, the registrants internal control over financial reporting; and 5. The
registrants other certifying officer and I have disclosed, based on our most
recent evaluation of internal control over financial reporting, to the
registrants auditors and the audit committee of the registrants board of
directors (or persons performing the equivalent functions): (a)
All significant deficiencies and material weaknesses in the design or operation
of internal control over financial reporting which are reasonably likely to
adversely affect the registrants ability to record, process, summarize and
report financial information; and (b)
Any fraud, whether or not material, that involves management or other employees
who have a significant role in the registrants internal control over financial
reporting. Date:
  March 31, 2006By:
  /s/ Shant S.
  HovnanianName:
  Shant S.
  HovnanianTitle:
  Chairman of
  the Board, President and Chief Executive Officer 2